The capital, announced at a Boston gathering at The 'Quin House, will bolster the PolyBio Research Foundation’s Long COVID Cure Initiative. By funding a dedicated clinical trials network, organizers intend to move beyond symptom management to investigate the biological root causes of the disease, such as persistent viral material and immune dysregulation. The initiative also intends to leverage this emerging infrastructure to address chronic Lyme disease.

Key donors, including Todd Park and Amy Geng, are backing a strategy focused on mechanistic trials that test combination therapies. During the event, physician-scientists Timothy Henrich and Michael Peluso highlighted that current diagnostic gaps leave many patients without clear answers or effective treatments. Through the VIPER diagnostic program, PolyBio Research Director Amy Proal is now working to validate tests that detect viral persistence, offering a potential roadmap for patients who have faced years of diagnostic uncertainty and limited care options.